Latest Investor Confidence News

Goodman Group has announced a total distribution of 15 cents per stapled security for the year ended 30 June 2025, combining dividends from its Hong Kong logistics arm and its Australian industrial trust.

Felix Group Holdings Ltd has announced a $1 million share purchase plan, offering eligible shareholders the chance to buy shares at $0.21 each starting 26 August 2025.

Embelton Limited reports a notable decline in revenue and profit for FY2025 amid a challenging construction market, yet maintains its dividend payout, signaling cautious optimism.

Asset Vision reported robust FY25 results with significant revenue and cash flow growth, achieving a debt-free status while advancing its AI-powered asset management platform.

Cyclone Metals Limited's shares have been suspended from trading on the ASX due to a non-compliant announcement, leaving investors in limbo until a suitable update is provided.

Vital Metals Limited has had its trading suspension lifted following announcements addressing an ASX Price and Volume Query and a new capital raise, signaling renewed market activity.

Vital Metals Limited has clarified the recent spike in its share price and trading volume, attributing it to a confidential capital raise and a positive scoping study amid a broader rare earths sector rally.

Australian Unity Office Fund’s planned $63.5 million sale of 150 Charlotte Street, Brisbane, has hit a snag with the purchaser defaulting on settlement, prompting a sharp valuation downgrade and withdrawal of distribution guidance.

WAM Microcap Limited has outperformed the ASX Small Ordinaries Index for the eighth consecutive year, posting an 18.8% portfolio gain and raising its fully franked dividend to 10.6 cents per share.

360 Capital Group reported a remarkable 1394% increase in statutory profit for FY25, maintaining dividends while advancing its real estate credit platform and announcing a substantial special distribution.

Legacy Minerals has secured NSW Government approval to recommence drilling at its Mt Carrington gold-copper project, unveiling fresh geophysical targets and backed by a recent $7.75 million capital raise.

Noxopharm has successfully completed the third dosing phase of its HERACLES trial for SOF-SKN™, confirming safety and moving forward to the highest dose cohort in this pioneering autoimmune drug study.